Get started
Author

Eloïse Planchat

Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
2010 · Mathilde Bayet-Robert, Fabrice Kwiatowski, et al. · Cancer Biology & Therapy · 407
PDF
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study
2016 · Hakim Mahammedi, Eloise Planchat, et al. · Oncology · 143
Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse
2010 · Emilie Thivat, Sophie Thérondel, et al. · BMC Cancer · 136
PDF
Temozolomide and unusual indications: Review of literature
2012 · Zuzana Tatar, Emilie Thivat, et al. · Cancer Treatment Reviews · 86
Importance of metabolic changes induced by chemotherapy on prognosis of early‐stage breast cancer patients: a review of potential mechanisms
2011 · E. Gadéa, E. Thivat, et al. · Obesity Reviews · 69
Late lines of treatment benefit survival in metastatic breast cancer in current practice?
2011 · E. Planchat, C. Abrial, et al. · The Breast · 29
Prognostic Value of Initial Tumor Parameters After Metastatic Relapse
2011 · E. Planchat, X. Durando, et al. · Cancer Investigation · 17
Panitumumab in combination with FEC 100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple-negative breast cancer (TNBC): Preliminary results of a multicenter neoadjuvant pilot phase II study.
2011 · J. Nabholtz, B. Weber, et al. · Journal of Clinical Oncology · 17
Valeur péjorative des variations de poids en cours de chimiothérapie dans le cancer du sein non métastatique : causes, mécanismes impliqués et stratégies préventives
2013 · Émilie Gadéa, Émilie Thivat, et al. · Bulletin du Cancer · 10
Does Regional Lymph Node Irradiation Improve the Outcome of N0 and pN0 Breast Cancer?
2009 · Olivier Gilliot, Xavier Durando, et al. · Cancer Investigation · 7
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line
2015 · Mélanie Pouget, Catherine Abrial, et al. · Oncology · 6
Long-term Significance (15 years) of Pathological Complete Response after Dose-dense Neoadjuvant Chemotherapy in Breast Cancer
2013 · Qian Wang-Lopez, Catherine Abrial, et al. · The Breast Journal · 4
Everolimus Plus Hormonotherapy (Ht) Induces Survival Gain in Late Metastatic Breast Cancer (Mbc) After Progression: Could this Line Be Better Than a Late New Chemotherapy (Ct) Line?
2014 · M. Pouget, E. Planchat, et al. · Annals of Oncology · 3
What is the survival length from the late lines of treatment in metastatic breast cancer?
2011 · M. Mouret-Reynier, E. Planchat, et al. · Journal of Clinical Oncology · 2
Pilot phase II study with docetaxel in combination with curcuminoids in patients with hormone-resistant prostate cancer (HRPC).
2011 · H. Mahammedi, E. Planchat, et al. · Journal of Clinical Oncology · 2
Everolimus in metastatic breast cancer (MBC): Clinical experience as a late treatment line.
2015 · Mélanie Pouget, Catherine Abrial, et al. · Journal of Clinical Oncology · 1
Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
2013 · Hakim Mahammedi, Mélanie Pouget, et al. · Journal of Clinical Oncology · 1
P3-14-01: Panitumumab in Combination with FEC 100 (5-Fluorouracile, Epirubicin, Cyclophosphamide) Followed by Docetaxel (T) in Patients with Operable, Triple Negative Breast Cancer (TNBC): Final Results of a Multicentre Neoadjuvant Pilot Phase II Study.
2011 · J-M Nabholtz, B Weber, et al. · Cancer Research · 1
7045 POSTER Docetaxel and Curcuminoids Combination in Patients With Hormone Resistant Prostate Cancer – a Phase II Study
2011 · H. Mahammedi, E. Planchat, et al. · European Journal of Cancer · 1
Abstract 3653: Cytotoxicity of curcumin combined with docetaxel at low or high dose implicates the antioxidant response and the glutathione cycle in MCF7 tumor cells: A metabolomics analysis
2010 · Mathilde Bayet-Robert, Eloïse Planchat, et al. · Cancer Research · 1
Weight Variation during Chemotherapy and Breast Cancer Prognostic.
2009 · S. Therondel, E. Thivat, et al. · Cancer Research · 1
Abstract 2694: The impact of curcumin plus docetaxel on neuroendocrine features, or not, in castration-resistant prostate cancer: A prospective study
2012 · Eloïse Planchat, Jean-Christophe Eymard, et al. · Cancer Research
Abstract 2707: Long-term significance (15 years) of pathological complete response after dose-dense neo-adjuvant chemotherapy in breast cancer
2012 · Qian Wang-Lopez, Catherine Abrial, et al. · Cancer Research
Traitement médical du cancer du sein et de la prostate métastatiques : potentialisation du docétaxel par la curcumine et amélioration de la prise en charge thérapeutique
2011 · Eloise Planchat · theses.fr (ABES)
Neoadjuvant chemotherapy (NCT) in 466 patients for operable breast cancer: Predictive factors for pathological response.
2010 · C. Abrial, X. Durando, et al. · Journal of Clinical Oncology
Works count: 25
Citation count: 944
H-index: 9
I10-index: 9
Year
Topic
Type